Julia TCW

Dr. Julia TCW

Icahn School of Medicine at Mount Sinai
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
Alex MontagneAlex Montagne
Alex Montagne
DNDaniel A. Nation
Daniel A. Nation
ASAbhay P. Sagare
Abhay P. Sagare
Giuseppe BarisanoGiuseppe Barisano
Giuseppe Barisano
MSMelanie D. Sweeney
Melanie D. Sweeney
BZBerislav V. Zlokovic
Berislav V. Zlokovic

23 June 2022 in Cell
Verified
Journal Article
Closed access
JTJulia TCW
Julia TCW
LQLu Qian
Lu Qian
NPNina H. Pipalia
Nina H. Pipalia
MCMichael J. Chao
Michael J. Chao
SLShuang A. Liang
Shuang A. Liang
AGAlison Goate
Alison Goate

2 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JHJi-Yeun Hur
Ji-Yeun Hur
GFGeorgia R. Frost
Georgia R. Frost
XWXianzhong Wu
Xianzhong Wu
CCChristina Crump
Christina Crump
SPSi Jia Pan
Si Jia Pan
YLYue-Ming Li
Yue-Ming Li

8 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
RNRyan A. Neff
Ryan A. Neff
MWMinghui Wang
Minghui Wang
SVSezen Vatansever
Sezen Vatansever
LGLei Guo
Lei Guo
CMChen Ming
Chen Ming
BZBin Zhang
Bin Zhang
Alzheimer’s disease (AD), the most common form of dementia, is recognized as a heterogeneous disease with diverse pathophysiologic mechanisms. In this study, we interrogate the molecular heterogeneity of AD by analyzing 1543 transcriptomes across five brain regions in two AD cohorts using an integrative network approach. We identify three major molecular subtypes of AD corresponding to different combinations of multiple dysregulated pathways, such as susceptibility to tau-mediated neurodegeneration, amyloid-β neuroinflammation, synaptic signaling, immune activity, mitochondria organization, and myelination. Multiscale network analysis reveals subtype-specific drivers such as GABRB2, LRP10, MSN, PLP1, and ATP6V1A. We further demonstrate that variations between existing AD mouse models recapitulate a certain degree of subtype heterogeneity, which may partially explain why a vast majority of drugs that succeeded in specific mouse models do not align with generalized human trials across all AD subtypes. Therefore, subtyping patients with AD is a critical step toward precision medicine for this devastating disease.

12 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
GNGloriia Novikova
Gloriia Novikova
MKManav Kapoor
Manav Kapoor
JTJulia TCW
Julia TCW
EAEdsel M. Abud
Edsel M. Abud
AEAnastasia G. Efthymiou
Anastasia G. Efthymiou
AGAlison Goate
Alison Goate
Genome-wide association studies (GWAS) have identified more than 40 loci associated with Alzheimer’s disease (AD), but the causal variants, regulatory elements, genes and pathways remain largely unknown, impeding a mechanistic understanding of AD pathogenesis. Previously, we showed that AD risk alleles are enriched in myeloid-specific epigenomic annotations. Here, we show that they are specifically enriched in active enhancers of monocytes, macrophages and microglia. We integrated AD GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and AD risk modification. We identify AD risk enhancers and nominate candidate causal genes among their likely targets (includingAP4E1, AP4M1, APBB3, BIN1, MS4A4A, MS4A6A, PILRA, RABEP1, SPI1, TP53INP1, andZYX) in twenty loci. Fine-mapping of these enhancers nominates candidate functional variants that likely modify AD risk by regulating gene expression in myeloid cells. In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain. Taken together, this study integrates AD GWAS with multiple myeloid genomic datasets to investigate the mechanisms of AD risk alleles and nominates candidate functional variants, regulatory elements and genes that likely modulate disease susceptibility.

21 December 2016 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Open access
PDF file
JTJulia TCW
Julia TCW
AGAlison Goate
Alison Goate
Alzheimer’s disease (AD) is characterized neuropathologically by neuronal cell loss, extracellular neuritic plaques composed of β-amyloid (Aβ), and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. Aβ is generated by proteolytic processing of the β-amyloid precursor protein (APP). Most individuals with Down syndrome (DS) have three copies of APP, leading to elevated APP expression, increased Aβ deposition, and characteristic AD neuropathology. Sequencing of APP in familial early-onset AD identified missense mutations that cause AD, while a recently discovered coding variant, APP A673T, reduces the risk for AD. Cellular and animal studies show that risk-associated mutations increase total Aβ levels, Aβ42 levels, or Aβ fibrillogenesis, while protective alleles reduce Aβ levels. Together, these studies provide compelling evidence for the Aβ hypothesis and suggest that therapeutics that reduces Aβ levels or Aβ fibrillogenesis should lower the risk for or prevent AD.